Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03275740
Recruitment Status : Recruiting
First Posted : September 8, 2017
Last Update Posted : February 3, 2021
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult subjects. The pharmacokinetics and pharmacodynamics will also be evaluated.

Condition or disease Intervention/treatment Phase
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Primary Immune Thrombocytopenia Drug: PF-06755347 intravenous Drug: Placebo intravenous Drug: PF-06755347 subcutaneous Drug: Placebo subcutaneous Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: single ascending dose study
Masking: Double (Participant, Investigator)
Masking Description: Double blind (investigator and subject), sponsor open
Primary Purpose: Treatment
Official Title: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING TO HEALTHY ADULT MALE PARTICIPANTS
Actual Study Start Date : July 17, 2017
Estimated Primary Completion Date : September 9, 2021
Estimated Study Completion Date : September 9, 2021


Arm Intervention/treatment
Experimental: PF-06755347 intravenous
intravenous administration
Drug: PF-06755347 intravenous
Single doses of PF-06755347 will be administered intravenously, at planned dose levels of intravenous dose level 1, 2, 3, 4, 5, 6, 7, 8 and 9.

Placebo Comparator: Placebo intravenous
intravenous administration
Drug: Placebo intravenous
Placebo comparator

Experimental: PF-06755347 subcutaneous
subcutaneous administration
Drug: PF-06755347 subcutaneous
single doses of PF-06755347 will be administered subcutaneously at planned dose levels of SC 1, SC 2 and SC 3.

Placebo Comparator: Placebo subcutaneous
subcutaneous administration
Drug: Placebo subcutaneous
placebo comparator




Primary Outcome Measures :
  1. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) [ Time Frame: Baseline (study day -2) through study completion (study day 36 for intravenous dose cohorts 1-5, and study day 71 for intravenous dose cohorts 6 - 9 and subcutaneous dose cohorts 1 - 3 ]
  2. Number of Participants With Clinical Laboratory Abnormalities [ Time Frame: Baseline, study days 2, 4, 6, 8, 11, 15, 22, 29 and 36 for i.v. dose cohorts 1 - 4, and Baseline, study days 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 50 and day 71 for i.v. dose cohorts 5 - 9 and for subcutaneous dose cohorts 1 - 3 ]
    Safety laboratory includes Hematology, Chemistry, Urinalysis, prothrombin time/international normalized ratio, partial thromboplastin time, D dimer, and fibrinogen

  3. Number of Participants With Categorical Vital Signs Data [ Time Frame: Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, and day 36 for i.v. dose cohorts 1 - 4 and Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 50 and day 71 for i.v. dose cohorts 5 - 9 and subcutaneous dose cohorts 1 - 3. ]
    Vital signs include blood pressure, pulse rate, and oral body temperature. Number of participants with maximum increase from Baseline in sitting SBP and DBP of greater than or equal to 30 mmHg will be reported

  4. Number of Participants With Abnormal Electrocardiogram (ECG) [ Time Frame: Baseline (study day 1, pre-dose), study days 1 (post dose), 2, 4, 6, 8, 11, 22, 36 (end of study visit for intravenous dose cohorts 1 - 5), and end of study visit day 71 for intravenous dose cohorts 6 - 9) and subcutaneous dose cohorts 1 - 3 ]
    Criteria for ECG abnormalities: maximum PR interval >=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) >=25 percent (%) for baseline value of >200 msec and Pctchg>=50% for baseline value of <=200 msec for PR interval, maximum QRS interval >=140 msec and a maximum IFB: Pctchg>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to <480 msec, 480 msec to <500 msec or >=500 msec and a maximum change of <=30change<60 or >=60 msec from baseline.


Secondary Outcome Measures :
  1. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcutaneous cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 9 and subcu cohorts ]
  2. Dose Normalized Maximum Observed Plasma Concentration Cmax [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 9 and subcu cohorts ]
  3. Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcutaneous cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 9 and subcu cohorts ]
  4. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcutaneous cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 9 and subcu cohorts ]
    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

  5. Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 9 and subcu cohorts ]
  6. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 9 and subcu cohorts ]
    AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).

  7. Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 9 and subcu cohorts ]
  8. Plasma Decay Half-Life (t1/2) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 9 and subcu cohorts ]
    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

  9. Apparent Clearance (CL) [ Time Frame: Baseline, 1, 3, 4, 5, 6, 8, 12 & 24 hours post dose for i.v. cohorts and baseline, 6 & 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 9 and subcu cohorts ]
    Steady state total body clearance equals infusion rate (zero order) divided by steady state plasma concentration of study drug (R0/Css)

  10. Incidence of Anti-Drug Antibody (ADA) [ Time Frame: Baseline, study days 8, 15, and 36 for all dose cohorts 1 - 5 plus day 71 for i.v. dose cohorts 6 - 9 and subcu cohorts ]
  11. Characterisation of biomarker changes [ Time Frame: Baseline (study day 1, pre-dose), 1, 3, 5, 8, and 24 hours post dose, study days 3, 4, 8, 15, and end of study visit (study day 36 for dose cohorts <=1mg/kg, and study day 71 for dose cohorts >1mg/kg) ]
    Baseline (study day 1, pre-dose), 1, 3, 5, 8, 12 and 24 hours post dose, study days 3, 4, 8, 15, and 36 for all dose cohorts plus day 71 for i.v. dose cohorts 5 - 9 and subcu cohorts.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male participants who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including oral temperature, blood pressure (BP) and pulse rate measurement, pulse oximetry, 12 lead ECG or clinical laboratory tests.
  • Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  • Chest X ray with no evidence of current, active tuberculosis (TB) or previous inactive TB, general infections, heart failure, malignancy, or other clinically significant abnormalities taken at Screening or within 3 months prior to Screening and read by a qualified radiologist.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Participants with a history of autoimmune disorders and other conditions that compromise or impair the immune system (including but not limited to: Crohns Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Graves disease, and asthma) or have a current positive result for the following; rheumatoid factor, anti-nuclear antibody, or abnormal free triiodothyronine (T3), free thyroxine (T4), thyroid stimulating hormone (TSH), or thyroid stimulating antibody (TSAb) suggestive of thyroid disease.

Subjects with a history of allergic or anaphylactic reaction to any drug including immunoglobulin.

  • History of active infections within 28 days prior to the screening visit.
  • Subjects with a history of or current positive results for any of the following serological tests: Hepatitis B surface antigen (HepBsAg), Hepatitis B core antibody (HepBcAb), Hepatitis C antibody (HCVAb) or human immunodeficiency virus (HIV).
  • Subjects with a history of thromboembolic events or current positive result for anti-cardiolipin antibody.
  • History of TB or active, latent or inadequately treated TB infection. All positive TB test result(s) are exclusionary
  • Male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03275740


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Locations
Layout table for location information
United States, Connecticut
Pfizer New Haven Clinical Research Unit Terminated
New Haven, Connecticut, United States, 06511
Belgium
Pfizer Clinical Research Unit Active, not recruiting
Brussels, Belgium, B-1070
New Zealand
Christchurch Clinical Studies Trust Ltd Recruiting
Christchurch, New Zealand, 8011
United Kingdom
Hammersmith Medicines Research (HMR) Active, not recruiting
London, United Kingdom, NW10 7EW
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03275740    
Other Study ID Numbers: B7801001
2018-003315-21 ( EudraCT Number )
First Posted: September 8, 2017    Key Record Dates
Last Update Posted: February 3, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombocytopenia
Immune System Diseases
Polyradiculoneuropathy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Purpura
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Polyneuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases